Erasmus MC - Department of Gastroenterology and Hepatology
Rotterdam, 3015 GD, Netherlands
Location status: Recruiting
NCT Number: NCT06944002
The goal of this study is to learn if cfDNA of milk-associated intestinal bacteria (MAIB) is detectable in the bloodstream. The primary question it aims to answer is:
- Does milk consumption simultaneously increase the number of MAIB cfDNA counts in blood samples, as it does in fecal samples?
Researchers will compare cfDNA counts of MAIB to those of fecal samples to assess whether the blood microbiome is a valid measure of the gut microbiome, utilizing a self-developed bioinformatics pipeline.
Participants will:
* Abstain from consuming any dairy products for ten days, followed by drinking milk for 7 consecutive days. * Provide blood and fecal samples before dairy abstinence, as well as at 0, 24, and 48 hours, and one week after the reintroduction of milk.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Rotterdam, 3015 GD, Netherlands
Location status: Recruiting
eDNA (ecological DNA) is a concept that is gaining popularity for making comprehensive descriptions of all organisms present in an ecosystem. Gut microbiomes can be considered a specific variant of eDNA. In theory, a description of the gut microbiome should contain all different kinds of microorganisms in our gastrointestinal tract, including bacteria, viruses, archaea, fungi and other organisms (e.g. worms and phages). In practice, making such descriptions is challenging because of spurious temporal changes and technical challenges (e.g. the commonly used 16S rRNA approach ignores many organisms). Nevertheless, making accurate descriptions is essential as it is generally accepted that the gut microbiome plays critical roles in maintaining host homeostasis and health.
To overcome the challenges in sampling the intestinal microbiome, most investigators currently rely on probing faeces. We have pioneered the field in developing improved technical approaches; for example, we previously performed a double-balloon endoscopic study in healthy volunteers to characterize this microbiome in its entirety. Problems with the faecal microbiome include its poor capture of the adherent flora (which seems the most relevant concerning human physiology), it is highly heterogeneous and can cause results to differ depending on which part of faecal samples was taken, and technological challenges, as many eukaryotes are quite resistant to DNA isolation protocols. Additionally, the faecal microbiome is dominated by diet, which can vary substantially from day to day in humans. For example, faecal material deriving from breakfast can have a significantly different microbiological composition compared to that derived from dinner. Hence, there is a call for alternatives.
The blood microbiome is a newly discovered way of probing the microbiome, integrating the colonization of all kinds of body sites, particularly the intestinal tract. It is speculated that the DNA fragments of various microorganisms enter the circulation through mechanisms that are yet fully understood. The gastrointestinal microbiome is considered a major source of blood microbiome, especially in the case of an impaired gut barrier, which can occur in various chronic diseases.
The description of the entire body of cell-free DNA fragments that derive from non-human origin is called the blood microbiome, even though it does not constitute living organisms, but rather their remnants. The blood microbiome signature has been reported as a predictable biomarker in differentiating patients with cancer from healthy individuals and even for distinguishing between different cancer types. However, the approach remains very controversial due to bioinformatical pitfalls. While we have invested substantial energy in resolving the issues involved, the field requires a formal proof-of-concept to progress. The current study is meant to provide this.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The participants will abstain from consumption of any dairy product for ten days and subsequently drink milk for seven consecutive days (700 ml per day), while concomitant consumption of other dairy products is also allowed.
Time frame: 10 days before milk consmuption (baseline), 0, 1, 2 and 7 days during milk consumption
Changes in blood and fecal Lactococcus DNA during milk consumption will be measured with shotgun sequencing technology.
Time frame: 10 days before milk consmuption, 0, 1, 2 and 7 days during milk consumption
Changes in other blood and fecal microbial DNA counts during milk consumption will be measured with shotgun sequencing technology.
Time frame: 10 days before milk consmuption, 0, 1, 2 and 7 days during milk consumption
Weight in kilograms and height in meters will be combined to report BMI in kg/m^2.
Time frame: 10 days before milk consmuption, 0, 1, 2 and 7 days during milk consumption
Changes in both systolic and diastolic blood pressure during milk consumption will be assessed with a blood pressure monitor.
Contact information is provided by the study sponsor or research team.
Junhong Su, PhD
CONTACT
Prof. Dr. Maikel P. Peppelenbosch, MD, PhD
CONTACT
Erasmus Medical Center
Other
The Effect of Milk Consumption on the Blood Microbiome in Healthy Volunteers
Acronym: MAMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686393
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT07669077
Healthy
Salt Lake City, Utah, United States
View Trial DetailsNCT07169630
Alzheimer s Disease, Cognition Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT07739238
Healthy
Balıkesir, In the USA Or Canada, Please Select..., Turkey (Türkiye)
View Trial Details